Figure 6.

Inhibition of GSK3β using SMI AZ3 in three additional MFS patient lines is beneficial

Three additional patient lines—DE35, DE37, and DE119—were differentiated into NC-VSMCs and treated with AZ3.

(A–C) Assays were performed as before to assess the effect of GSK3β inhibition on proteolysis as assessed by DQ-gelatin intensity (A and B) and MMP2 and MMP9 mRNA expression (C).

(D and E) Apoptosis in these additional lines was also assayed.

150 μm scale bars throughout. n = 3 independent experiments. Data are represented as mean ± SEM.